Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

作者
Dengfeng Ren,Fangchao Zheng,Junhui Zhao,Guoshuang Shen,Raees Ahmad,Shui-Sheng Zhang,Yu Zhang,Jie Kan,Li Dong,Ziyi Wang,Fuxing Zhao,Jiuda Zhao
出处
期刊:World Journal of Clinical Cases [Baishideng Publishing Group]
卷期号:6 (10): 373-383 被引量:6
标识
DOI:10.12998/wjcc.v6.i10.373
摘要

AIMTo investigate the safety and efficacy of S-1 plus oxaliplatin (SOX) as an adjuvant chemotherapy regimen in gastric cancer (GC) after D2 dissection. METHODS GC Patients who underwent D2 gastrectomy fromSeptember 2009 to December 2011 in four Chinese institutions were enrolled.Patients with stage ⅠB-ⅢC GC, who received adjuvant SOX treatment were matched by propensity scores with those who underwent surgery alone and those who conducted capecitabine plus oxaliplatin (XELOX) regimen.Disease-free survival (DFS) and overall survival (OS) were compared among the groups.In addition, adverse events in SOX patients were analyzed.Of 1944 GC patients who underwent D2 dissection, 867 were included for analysis.One hundred and seventeen patients treated with SOX were matched to 234 patients who conducted surgery alone.Fifty-seven patients treated with SOX were matched to 57 patients who received XELOX.The estimated five-year DFS was 57.5% in the adjuvant SOX group which was higher than that (44.6%) in the surgery alone group (P = 0.001); and the estimated five-year OS was 68.3% which was higher than that (45.8%) of surgery alone group (P < 0.001).Survival benefit was also revealed in stage III and > 60 years old subgroups (P < 0.001 and P = 0.015, respectively).Compared with XELOX regimen, SOX showed no significant difference in DFS (P = 0.340) and OS (P = 0.361).The most common ≥ 3 grade adverse events of SOX regimen were neutropenia (22.6%), leukopenia (8.9%) and thrombocytopenia (5.6%). CONCLUSIONCompared with surgery alone, SOX regimen significantly improves the long-term survival and has acceptable toxicity in patients with stage ⅠB-ⅢC GC after D2 dissection.It may be a novel adjuvant chemotherapy regimen in GC patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
摇滚谬中庸完成签到 ,获得积分10
1秒前
2秒前
Hollen完成签到 ,获得积分10
2秒前
ferritin完成签到 ,获得积分10
2秒前
slim完成签到,获得积分10
3秒前
半序完成签到 ,获得积分10
3秒前
小妮子完成签到,获得积分10
3秒前
奋斗蝴蝶发布了新的文献求助10
3秒前
思源的应助被aaa采纳,获得10
4秒前
pluto的应助被望舒采纳,获得10
4秒前
夕荀完成签到,获得积分20
4秒前
初景发布了新的文献求助10
4秒前
哈哈发布了新的文献求助10
4秒前
水猫硕士完成签到,获得积分10
4秒前
东风知我欲完成签到,获得积分10
5秒前
研友_ZG4ml8发布了新的文献求助10
5秒前
木子草右田力完成签到 ,获得积分10
5秒前
刘思琪发布了新的文献求助10
6秒前
iggyxhjtl完成签到,获得积分10
6秒前
瓶瓶大王完成签到 ,获得积分10
6秒前
傅凡桃完成签到,获得积分10
6秒前
大模型的应助被拉长的砖家采纳,获得10
6秒前
里里完成签到,获得积分10
6秒前
kyhappy_2002完成签到,获得积分10
6秒前
光亮的洙完成签到,获得积分10
7秒前
7秒前
天天向上的应助被路遥知马力采纳,获得10
8秒前
8秒前
榴莲味月饼完成签到 ,获得积分10
8秒前
工作热情仔的应助被xyz采纳,获得100
8秒前
lijiaqi完成签到 ,获得积分10
8秒前
zhi完成签到,获得积分10
9秒前
yu发布了新的文献求助20
9秒前
9秒前
戒骄戒躁完成签到 ,获得积分10
9秒前
认真的小刺猬完成签到,获得积分10
10秒前
10秒前
彭彭完成签到,获得积分10
10秒前
慕青的应助被研友_ZG4ml8采纳,获得10
11秒前
图南完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039